Collectively, these results demonstrate that C1GALT1 is highly expressed in ES cells and that its genetic or pharmacological inhibition leads to reduced EWSR1::FLI1 levels and function, suggesting it is a promising therapeutic target in ES. Here, C1GALT1 is linked to Ewing sarcoma.